Recent Updates
Recently added Catalysts
DARE Positive Sentiment

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

Key Takeaway: Daré Bioscience has made its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference available for on-demand viewing. The presentation, led by CEO Sabrina Martucci Johnson, covers the company's recent developments and future direction. The conference will take place from September 14-16, 2026, in New York, where management will meet with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation highlights recent corporate and clinical developments.
  • Focus on women's health with innovative solutions.
  • Management is actively engaging with investors at the conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~5 mo
High dilution risk
Lead asset
Lopinavir/ ritonavir
Phase 2 · Human Papilloma Virus (HPV)

Full Press Release Details

View the video webcast here
SAN DIEGO , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here .
The presentation, featuring Sabrina Martucci Johnson , President and Chief Executive Officer of Daré Bioscience, provides an overview of the Company as well as recent corporate and clinical developments.
The on-demand presentation is available for viewing beginning today, September 11, 2026 , at 7:00 a.m. ET , and can also be accessed through the Presentations, Events & Webcasts page of the Investors section of the Company’s website ( darebioscience.com ). The presentation will be accessible for 90 days.
Management will be on-site at the conference, being held September 14–16, 2026, in New York, NY , for one-on-one meetings with investors. For more information, please visit the conference website .
ABOUT DARÉ BIOSCIENCE, INC.
Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com .
Contact: Daré Bioscience Investor Relations innovations@darebioscience.com
Source: Daré Bioscience, Inc.

Frequently Asked Questions

What is the focus of Daré Bioscience?

Daré Bioscience focuses on women's health, addressing gaps in care with innovative solutions.

When is the H.C. Wainwright conference?

The H.C. Wainwright conference is scheduled for September 14-16, 2026.

How can I view the presentation?

The presentation is available for on-demand viewing on the company's website.

Who is presenting for Daré Bioscience?

Sabrina Martucci Johnson, the CEO, is presenting for Daré Bioscience.

Last updated: Sep 11, 2026